Finder's Pick for
Beginners
Champions Oncology is a biotechnology business based in the US. Champions Oncology stocks (CSBR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $9.54 – an increase of 2.24% over the previous week. Champions Oncology employs 194 staff and has a trailing 12-month revenue of around $46.8 million.
How to buy stocks in Champions Oncology
- Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CSBR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Finder's Pick for
Global Trading
Finder's Pick for
Commodity Stocks
Finder's Pick for
Free Trades
What's in this guide?
- Can I buy shares in Champions Oncology?
- Has coronavirus impacted Champions Oncology shares?
- Champions Oncology shares summary
- Compare share dealing platforms
- Is Champions Oncology stock a buy or sell?
- Champions Oncology performance over time
- Are Champions Oncology shares over-valued?
- Champions Oncology's financials
- How volatile are Champions Oncology shares?
- Does Champions Oncology pay a dividend?
- Have Champions Oncology shares ever split?
- Other common questions
Champions Oncology stock price (NASDAQ:CSBR)
Use our graph to track the performance of CSBR stocks over time.Champions Oncology shares at a glance
Information last updated 2022-06-24.
| Latest market close | $7.76 |
|---|---|
| 52-week range | $6.81 - $11.25 |
| 50-day moving average | $7.54 |
| 200-day moving average | $8.47 |
| Wall St. target price | $14.67 |
| PE ratio | 861.1112 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.01 |
Compare stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
1 - 6 of 6
Online stock trading
Is it a good time to buy Champions Oncology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Champions Oncology price performance over time
Historical closes compared with the close of $7.76 from 2022-06-27
| 1 week (2022-06-21) | 2.24% |
|---|---|
| 1 month (2022-05-24) | 5.15% |
| 3 months (2022-03-24) | -2.76% |
| 6 months (2021-12-24) | N/A |
| 1 year (2021-06-28) | -26.72% |
|---|---|
| 2 years (2020-06-26) | -13.59% |
| 3 years (2019-06-28) | 7.83 |
| 5 years (2017-06-28) | 173.24% |
Is Champions Oncology under- or over-valued?
Valuing Champions Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Champions Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Champions Oncology's P/E ratio
Champions Oncology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 861x. In other words, Champions Oncology shares trade at around 861x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Champions Oncology's EBITDA
Champions Oncology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.6 million.
The EBITDA is a measure of a Champions Oncology's overall financial performance and is widely used to measure a its profitability.
Champions Oncology financials
| Revenue TTM | $46.8 million |
|---|---|
| Operating margin TTM | 0.58% |
| Gross profit TTM | $19.6 million |
| Return on assets TTM | 0.57% |
| Return on equity TTM | 2.56% |
| Profit margin | 0.47% |
| Book value | $0.68 |
| Market capitalisation | $104.8 million |
TTM: trailing 12 months
Champions Oncology share dividends
We're not expecting Champions Oncology to pay a dividend over the next 12 months.
Have Champions Oncology's shares ever split?
Champions Oncology's shares were split on a 1:12 basis on 11 August 2015. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Champions Oncology shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Champions Oncology shares which in turn could have impacted Champions Oncology's share price.
Champions Oncology share price volatility
Over the last 12 months, Champions Oncology's shares have ranged in value from as little as $6.81 up to $11.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Champions Oncology's is 1.0272. This would suggest that Champions Oncology's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Champions Oncology overview
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc.
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing
Find the best investment newsletters in Canada
Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.
Read more…
Sectors and stocks that might protect you from rising interest rates
Here are some investment ideas that could do well despite rising interest rates.
Read more…
Online gaming stocks
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Read more…More guides on Finder
-
Find the best investment newsletters in Canada
Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.
-
How to buy Onfolio Holdings (ONFO) stock in Canada when it goes public
Everything we know about the Onfolio Holdings IPO plus information on how to buy in.
-
How to buy Acadian Timber stock in Canada
Steps to owning and managing ADN stock, with 24-hour and historical pricing before you buy.
-
How to buy Mobilicom Limited (MOB) stock in Canada when it goes public
Everything we know about the Mobilicom Limited IPO plus information on how to buy in.
-
How to buy Consumer Staples Select Sector SPDR Fund stock in Canada
Steps to owning and managing XLP stock, with 24-hour and historical pricing before you buy.
-
How to buy Schwab U.S. REIT ETF stock in Canada
Steps to owning and managing SCHH stock, with 24-hour and historical pricing before you buy.
-
How to buy iShares US Consumer Staples ETF stock in Canada
Steps to owning and managing IYK stock, with 24-hour and historical pricing before you buy.
-
How to buy Vanguard Real Estate Index Fund ETF Shares stock in Canada
Steps to owning and managing VNQ stock, with 24-hour and historical pricing before you buy.
-
How to buy SPDR S&P Insurance ETF stock in Canada
Steps to owning and managing KIE stock, with 24-hour and historical pricing before you buy.
-
How to buy Financial Select Sector SPDR Fund stock in Canada
Steps to owning and managing XLF stock, with 24-hour and historical pricing before you buy.